Updates in Cardiac Amyloidosis

Updates in Cardiac Amyloidosis are supported in part by an independent educational grant from Pfizer.

The Institute for Future Health is hosting a hybrid (in-person and Livestream) conference focused on building the
knowledge of cardiac amyloidosis amongst Arizona clinicians. This event was exclusively dedicated to cardiac amyloidosis, a disease of protein misfolding that leads to congestive heart disease, disabling neuropathy, and other systemic conditions. Cardiac Amyoidosis can be caused by transthyretin or light-chain amyloidosis. the pace of knowledge in this field is greatly accelerating, and it is important for clinicians and scientists
to be aware of new developments.

Thank you to:
Alnylam, American College of Cardiology – Arizona Chapter
Arizona State University ASU Office of Interprofessional Continuing Health Education

AGENDA > link to PDF (https://www.dropbox.com/s/vjksa645vd8ax2p/Agenda_CardiacAmyloidosisCME-FINAL_-Online.pdf?dl=0)

Updates in Cardiac Amyloidosis 2023 | Event Videos:
1 – Welcome | Updates in Cardiac Amyloidosis 2023
2 – Building a Community Around ATTR CA: Lessons
3 – Red Flags, Clinical Presentation and Diagnostic Algorithm for Cardiac ATTR
4 – Epidemiology, Health Equity, Population Screening in ATTR CA
5 – Echocardiography and Strain Imaging in CA
6 – Nuclear Cardiology Diagnosis
7 Panel discussion led by moderators
8 – Role of Genetic Testing
9 – Workup of Monoclonal Gammopathy
10 – Neurological Presentations of ATTR | Updates in Cardiac
11 – Role of Cardiac and Non-Cardiac Biopsy/Pathology
12 – Amyloid (ATTR, AL) Therapy, Including Navigating Prior Authorization | UCA 2023
13 – Panel discussion by moderators | Updates in Cardiac
14 – Keynote Speaker: TTR Amyloid: How to Find Early and
15 Closing Remarks